Physician profile
Robert T Keller
NPI 1962445346
$25,851.31
in general payments reported to CMS, 2019-2025
63 companies · $2,365 in 2025
The $2,365 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,789 · 2020: $1,614 · 2021: $4,756 · 2022: $2,979 · 2023: $2,215 · 2024: $3,132 · 2025: $2,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,712.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $4,807.40 | 2019-2025 | |
| Novo Nordisk INC | $2,531.01 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $2,288.52 | 2019-2023 | Camzyos |
| Glaxosmithkline, LLC. | $2,047.92 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $1,949.37 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Amgen INC. | $1,888.39 | 2019-2025 | Repatha, Evenity, Otezla |
| Abbvie INC. | $1,699.41 | 2019-2024 | |
| Lilly USA, LLC | $1,174.00 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $742.60 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $470.13 | 2019-2024 | Xifaxan, Trulance, Cycloset |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $449.67 | 2022-2025 | Caplyta |
| Amarin Pharma, INC. | $435.95 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $348.90 | 2024-2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $347.26 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $326.20 | 2019-2022 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.